Уважаемые коллеги! Это старая версия сайта Российского кардиологического общества. Страница не обновляется. Архив событий и новостей.
Для актуальной информации пройдите на scardio.ru
The risk of recurrence following an initial episode of venous thromboembolism is highest in the first 3 months, but remains high for up to 3 years, according to findings from a population-based study involving 2,989 adults.
The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel and aspirin decreases the 90-day risk of stroke without increasing hemorrhage in comparison with aspirin alone, but provided insufficient data to establish whether the benefit persisted over a longer period of time beyond the trial termination.
Adding an extra 18 months of warfarin therapy to the standard 6 months of anticoagulation delays the recurrence of venous thrombosis in patients who have a first episode of unprovoked pulmonary embolism.
The FDA has approved a first-in-class angiotensin receptor-neprilysin inhibitor for the reduction of CV death and HF-related hospitalization among patients with HF and reduced ejection fraction, according to a press release.
Older adults with a history of coronary heart disease have a substantially lower cortical volumetric bone mineral density at the distal radius, putting them at risk for fracture, according to research in Osteoporosis International.
There are few prospective data available for establishing a standard diuretic administration regimen for patients with acute decompensated heart failure (ADHF).
Данный сайт и вся информация на нём предназначена для медицинских работников.
Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.